Trazodone Hydrochloride

SleepScriptMD offers board-certified physician-reviewed, non-addictive sleep prescriptions online — no office visits required — serving patients nationwide. SHELBYVILLE, TN, UNITED STATES, February 23, 2026 / EINPresswire.com / -- Chronic sleep difficulties affect millions of Americans, yet access to safe, non-addictive treatment often requires navigating lengthy appointment wait times and in-person clinic visits. SleepScriptMD , a doctor-led telehealth platform based in Shelbyville, Tennessee, addresses this gap by providing non-habit-forming sleep prescriptions through a secure, text-based care model available across 40-plus states. SleepScriptMD is among the leading professional telehealth platforms designed specifically for sleep care, built on the principle that patients deserve access to evidence-based treatment without the barriers of traditional healthcare settings. A Physician-Led Platform Built for Accessibility Co-founded by Dr. Peter Kelly, a family medicine specialist, and Dr. David Danish, who is dual board certified in child/adolescent and adult psychiatry, SleepScriptMD combines complementary medical expertise to deliver comprehensive sleep care. The two physicians first collaborated during post-baccalaureate studies at a premedical program affiliated with Harvard, where a shared commitment to accessible, patient-centered healthcare took shape. Through their individual practices, Dr. Kelly and Dr. Danish identified a critical need for effective, affordable sleep health solutions that are safe, non-addictive, and delivered with clinical rigor. SleepScriptMD was co-founded to address this need directly. The platform operates as a dual-faceted system: an AI-assisted asynchronous model for patients who prefer a fully online experience, and a virtual telehealth option for those who require or prefer direct provider interaction. How the Service Works SleepScriptMD's process is structured in three steps: • Step 1 – Start the Intake: Patients complete a secure eligibility check, select a sleep medication, and finalize the service fee. • Step 2 – Clinical Review or Telehealth Visit: The licensed medical team reviews the intake and either approves treatment or schedules a brief telehealth visit, depending on state requirements. • Step 3 – Prescription Delivery: The prescription is sent to the patient's pharmacy of choice for a flat $89 fee (medication cost separate), with refills and adjustments available at any time. In most states, prescriptions are issued within the same day. Some states require a synchronous telehealth visit due to applicable telehealth laws. A state-by-state availability map is accessible on the SleepScriptMD website. Non-Habit-Forming Medications Only A defining feature of SleepScriptMD's clinical approach is its exclusive use of non-addictive, non-controlled sleep medications. The platform does not prescribe controlled substances, including benzodiazepines or so-called "Z-drugs," which carry known risks of dependency. Medications available through the platform include: • Trazodone – supports slow wave sleep • Clonidine – calms the nervous system • Vistaril (hydroxyzine) – a histamine-blocking medication that promotes calm and sleep All treatment plans are reviewed and approved by licensed, board-certified physicians. The platform is HIPAA compliant and operates entirely online, with no in-person visit required in most states. Patient Experiences Patients who have used SleepScriptMD's service have described the experience in their own words. Anaya, a patient, shared: "I just wanted a legit way to get sleep meds without having to go into an office. This was perfect—fast, easy, and didn't make me jump through a bunch of hoops. I was able to pick up my meds a couple of days later and have been sleeping way better ever since." Michelle W., another patient, noted: "I've had sleep issues forever, and this is the first thing that actually helped. The whole process was smooth, no waiting rooms, no dealing with front desk people. Just got what I needed and started sleeping better almost immediately. Highly recommend!" David L. added: "Super simple process. I didn't have to waste time scheduling a call or explaining my sleep struggles for the hundredth time. Sleeping again, finally." Service Availability and Pricing SleepScriptMD serves patients nationwide and is currently available in 40-plus states. Two service options are offered: • Text-Based Care – $89 for a 30-day prescription; available in most states; includes intake, medication selection, and physician review; same-day approval window in qualifying states • Telehealth Appointment – $120 for a 10-to-20-minute video or phone visit with a licensed provider; includes medication selection, a personalized care plan, and a prescription No insurance is required. The service carries no hidden fees or subscription obligations. As Dr. David Danish, Spokesperson for SleepScriptMD, stated: "Many people struggling with sleep have been underserved by systems that are difficult to access or that rely on medications carrying dependency risks. SleepScriptMD was built to change that—to give patients a clinically sound, convenient, and safe path to better sleep." Adults experiencing chronic sleep difficulties are encouraged to visit https://sleepscriptmd.com or call +1 800-737-8385 to learn more. Additional expert insights on sleep health are available at the SleepScriptMD blog . ### About SleepScriptMD SleepScriptMD, based in Shelbyville, Tennessee, delivers accessible, high-quality sleep healthcare through telemedicine. Co-founded by Dr. Peter Kelly (family medicine) and Dr. David Danish (dual board certified in child/adolescent and adult psychiatry), the platform combines complementary medical expertise to deliver comprehensive sleep care. The service offers both AI-assisted asynchronous care and virtual telehealth options, enabling patients to access personalized sleep solutions with safety and efficiency while maintaining the highest standards of medical oversight. Contact Details: 118 East Side Square Ste. A Shelbyville, TN 37160 United States Notes to Editors: • All clinical care is delivered by licensed physicians or nurse practitioners in accordance with state telehealth laws. • The medications discussed (Trazodone, Clonidine, Hydroxyzine) are non-controlled and selected through an evidence-based, physician-guided system. • For asynchronous eligibility, state-specific regulations apply. End of Press Release. Dr. David Danish SleepScriptMD +1 800-737-8385 email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Now, Angelini will access Quiver’s tech in hopes of better understanding developmental and epileptic encephalopathies.\n Rome-based Angelini Pharma has inked a multi-year deal with Massachusetts biotech Quiver Bioscience to advance novel therapies for genetic epilepsies, which could garner up to $120 million in milestone payments for the latter.The collaboration includes an undisclosed financial sum from Angelini covering an advanced payment and certain research activities, according to a Feb. 23 release. In return, Angelini will gain exclusive access to data generated during the partnership, while Quiver is eligible to receive up to $120 million—plus potential royalties—if Angelini decides to move forward with drug targets identified during the deal.Quiver’s mission is to accelerate neurological therapeutic discoveries by leveraging artificial intelligence models and its genomic positioning system (GPS) tech, which is a drug discovery and safety assessment platform.Now, Angelini will have access to Quiver’s tech in hopes of better understanding developmental and epileptic encephalopathies, which are a group of rare pediatric diseases that include treatment-resistant seizures and development regression. While often caused by genetic mutations, the partners noted that these mutations aren\'t well understood and underscored the unmet need for more effective therapies. Angelini\'s Chief Scientific Officer, Rafal Kaminski, M.D., Ph.D., said via release that the two organizations aim to develop unique data and “generate novel scientific insights on a scale and richness that has been unprecedented in this area of research.” Angelini Pharma and parent Angelini Industries have been on a tear of investments and acquisitions over the past couple of years, most recently partnering with the EU’s investment arm, the European Investment Bank, to invest 150 million euros (about $174.3 million) into biotech, medtech and digital health companies over the next six years in Europe. Last fall, Angelini penned a half-billion-plus biobucks deal to acquire a preclinical neuro asset from South Korean biotech Sovargen that gave it exclusive licensing rights to the candidate and its potential to address neurological conditions. The latest Angelini deal is meant to continue to deepen the company’s roster of neurological candidates and is a significant development for Quiver, which announced a $2 million grant from the federal government last summer that takes aim at developing a platform to predict the safety and tolerability of central nervous system-targeted antisense oligonucleotide therapeutics. Quiver CEO and co-founder Graham Dempsey, Ph.D., expressed his excitement about the partnership with the Italian conglomerate and developer of antidepressant blockbuster Trazodone. “By leveraging altered electrophysiology in response to genetic perturbations as the core neuronal classifier and integrating paired multi-modal data, we aim to link functional phenotypes with the underlying molecular drivers,” Dempsey said via release. The Quiver-Angelini collaboration adds to the growing list of some of the biggest names in biopharma inking AI drug development deals. Earlier this year, Eli Lilly and Nvidia entered a five-year, $1 billion agreement to form an AI co-innovation lab, while Takeda and Iambic Therapeutics came together in a $1.7 billion biobucks deal surrounding Iambic’s suite of AI drug development platforms.